Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 12/20 | 0.50 |
| ▸ | TACR1 | P25103 | 6/20 | 0.40 |
| ▸ | TACR3 | P29371 | 4/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258113 | 1.00 | TACR2 (0.50) | TACR2TACR1TACR3PRCPELANE | |
| SCHEMBL4255036 | 0.99 | TACR2 (0.50) | TACR2TACR1TACR3PRCPELANE | |
| SCHEMBL5814301 | 0.99 | TACR2 (0.50) | TACR2TACR1TACR3PRCPELANE | |
| SCHEMBL4263331 | 0.96 | TACR2 (0.48) | TACR2TACR1TACR3PRCPELANE | |
| SCHEMBL4410645 | 0.92 | TACR2 (0.42) | TACR2TACR1TACR3PRCP | |
| SCHEMBL4421156 | 0.90 | TACR2 (0.41) | TACR2TACR1TACR3PRCP | |
| SCHEMBL5815270 | 0.90 | TACR2 (0.41) | TACR2TACR1TACR3PRCP | |
| SCHEMBL4268513 | 0.90 | TACR2 (0.42) | TACR2TACR1TACR3PRCPCNR2 | |
| SCHEMBL4259228 | 0.90 | TACR2 (0.40) | TACR2TACR1TACR3 | |
| SCHEMBL5013763 | 0.90 | TACR2 (0.41) | TACR2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006062478-A1 | NOVEL TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | claimed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | claimed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2006062478-A1 | NOVEL TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |